Ascletis Pharma (HKG:1672) obtained investigational new drug clearance from the U.S. Food and Drug Administration (FDA) for the phase I study of ASC3, according to a Tuesday Hong Kong bourse filing.
The drug is being tested for the treatment of obesity.
Tetratherix (ASX:TTX) said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.
Bharat Electronics (NSE:BEL, BOM:500049) has secured additional orders worth 10.8 billion Indian rupees within one month, according to a filing to the Indian stock exchanges on Monday.Major orders received since May 25 include communication equipment, radars, CBRN protection systems, seekers, avionics, upgrades, spares, and services, among others.
Chasen 9 (SGX:5NV) secured around 470 million Indian rupees worth of solar energy and electric vehicle battery contracts in India, according to a Monday filing with the Singapore Exchange.The deals include an electronics manufacturing services contract for specialist relocation services and an integrated solar manufacturing facility contract commissioned at the Reliance Industries' Dhirubhai Ambani Green Energy Giga Complex in Gujarat.